Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients

Suzuki, Kouji; Tsuji, Shigeyoshi; Fukushima, Yaeko; Nakase, Takanobu; Hamada, Masayuki; Tomita, Tadanori; Yoshikawa, Hideki

doi:10.1007/s10165-012-0678-x

Cited by 7 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Однако в недавнем рандомизированном контролируемом исследовании популяции постменопаузальных китайских женщин средних лет и в пожилом возрасте дополнительное добавление к витамину K 2 в дозе 90 мкг в день препаратов кальция (500 мг в день) и витамина D (в дозе 400 МЕ НАУЧНЫЙ ОБЗОР в день) не показало улучшения эффекта в сравнении с монотерапией витамином K 2 [44]. Единичные исследования применения витамина K 2 с антирезорбтивными препаратами, в частности с бисфосфонатами, также продемонстрировали неоднозначные результаты: так, комбинация с алендронатом была ассоциирована с повышением МПКТ в бедренной кости у женщин с постменопаузальным остеопорозом [45], в то время как комбинированная терапия с ризедронатом не показала эффективности по сравнению с монотерапией ризедронатом [46].…”

Section: влияние витамина K 2 на костную тканьunclassified

Bone metabolism in diabetes mellitus: focus on vitamin K2

Radugin

Karonova

2022

Osteopor Bone Dis

View full text Add to dashboard Cite

Diabetes mellitus (DM) type 2 is reported to be among the most common diseases both worldwide and in Russian Federation, whereby chronic implications that develop under hyperglycemia pose a serious socioeconomic problem. Besides of classic microvascular complications like diabetic retinopathy, nephropathy and polyneuropathy it’s recently worthy of note the presence of high fracture risk in DM type 2 even in normal bone mass density, known as “diaporosis” or “diabetoporosis” considered as another DM complication. It is well known that osteoporosis is reported to be widespread disease as same as DM type 2 and likewise is a widely abundant in older age that makes their combination is really possible in a single patient. Taking into account high social value and disability due to osteoporotic fractures and chronic DM type 2 complications it becomes necessary to continue physiologic and biochemical basis investigations of bone formation and remodeling and pathogenesis of osteoporosis development in the context of chronic hyperglycemia. One of the fairly new factors which the experts believe it is link between impaired glucose metabolism and bone remodeling is osteocalcin which concentration is dependent on vitamin K2 maintenance considered as a potential agent in osteoporotic fractures prevention. In this review current information on vitamin K2 influence on bone status and possibility of using this nutrient in clinical practice in the focus on patients with DM will be covered.

show abstract

Section: влияние витамина K 2 на костную тканьunclassified

Bone metabolism in diabetes mellitus: focus on vitamin K2

Radugin

Karonova

2022

Osteopor Bone Dis

View full text Add to dashboard Cite

show abstract

“…RA increases the risk of osteoporosis and fractures which may also be associated with secondary osteoporosis caused by glucocorticoid therapy. Early prevention of osteoporosis is, therefore, important to prevent fractures and to improve quality of life and life expectancy [5]. Previous clinical studies indicated that vitamin K 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis [6].…”

Section: Introductionmentioning

confidence: 99%

Effects of vitamin K₂ combined with methotrexate against mitogen‐activated peripheral blood mononuclear cells of healthy subjects and rheumatoid arthritis patients

Tahara

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Background: Methotrexate (MTX) is used as anchor drug for patients with early and established rheumatoid arthritis (RA). Vitamin K 2 administration was also reported to be associated with decreased disease activity in RA.Objectives: Immunosuppressive pharmacodynamics of vitamin K 2 combined with MTX was investigated.Methods: Mitogen-activated peripheral blood mononuclear cells (PBMCs) were used to evaluate immunosuppressive pharmacodynamics of drugs in vitro.Results: Vitamin K 2 alone dose-dependently suppressed T cell mitogenactivated proliferation of PBMCs of both healthy subjects and RA patients.446.5 and 2232.5 ng/mL vitamin K 2 significantly decreased the IC 50 values of MTX on the proliferation of PBMCs of RA patients, with little influences on the pharmacodynamics of MTX in the healthy PBMCs. 4465 ng/mL vitamin K 2 potentiated the pharmacodynamics of MTX in both RA patients and healthy PBMCs. The additional effects of vitamin K 2 to potentiate the suppressive effects of MTX seemed not to be related to the regulation of CD4 + CD25 + T cells or CD4 + CD25 + Foxp3 + Treg cells. MTX alone at 100 ng/mL significantly decreased the percentage of CD4 + T cells in PBMCs of healthy subjects (p < 0.001) with a slight influence in that of RA patients (not significant) and the combination did not show synergistic inhibitory effect. Vitamin K 2 alone tended to suppress the secretion of IL-17, IFN-γ, and TNF-α from the activated PBMCs of RA patients with smaller influences on the cytokine productions from healthy PBMCs. These additional effects of vitamin K 2 were also observed in combination with MTX. Conclusion:The above information may partially elucidate the potentiation effects of vitamin K 2 on the immunosuppressive efficacy of MTX.

show abstract

Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis

et al. 2015

View full text Add to dashboard Cite

The aim of this observational, nonrandomized study was to compare the effects of 12 months of monthly minodronate (MIN; 50 mg/month) monotherapy and MIN combination therapy with vitamin K2 (VK; 45 mg/day) or eldecalcitol (ELD; 0.75 μg/day) in treatment-naïve patients with primary osteoporosis. Patients (n = 193; 178 postmenopausal women and 15 men; mean age 71.6 years) were treated with (1) MIN monotherapy (n = 63), (2) MIN plus VK combination therapy (n = 50), or (3) MIN plus ELD combination therapy (n = 80) for 12 months. Changes in bone mineral density (BMD) and the levels of serum bone turnover markers were monitored. No significant difference was observed in baseline BMD among the three groups. After 12 months, BMD increased by 2.93, 4.65, and 6.55 % in the lumbar spine, 0.66, 2.57, and 3.42 % in the total hip, and 0.05, 2.06, and 3.58 % in the femoral neck in groups 1, 2, and 3, respectively. The BMD increase induced by MIN plus ELD combination therapy was significantly greater than that induced by MIN monotherapy in the lumbar spine (P = 0.0002), total hip (P = 0.003), and femoral neck (P = 0.004), and also that induced by MIN plus VK combination therapy in the lumbar spine (P = 0.03). MIN plus ELD combination therapy compared with MIN monotherapy resulted in a greater decrease in serum procollagen type I N-terminal propeptide levels (-37.4 % vs -54.6 %; P = 0.001) and tartrate-resistant acid phosphatase isoform 5b levels (-41.1 % vs -52.9 %; P = 0.009) at 3 months, and a greater decrease in procollagen type I N-terminal propeptide levels (-64.3 % vs -50.3 %; P = 0.03) and a decrease in intact parathyroid hormone levels (-12.3 % vs 14.0 %; P = 0.01) at 12 months. Combination therapy with MIN and VK or ELD for 12 months showed additive effects in decreasing the levels of bone turnover markers compared with MIN monotherapy, whereas MIN plus ELD combination therapy resulted in the highest BMD increase compared with MIN monotherapy and MIN plus VK combination therapy.

show abstract

Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients

Abstract: Combined therapy with alendronate and VitK2 decreases bone metabolism marker levels and serum ucOC levels, and increases lumbar spine and femoral neck bone density in postmenopausal RA patients with abnormal ucOC levels and osteoporosis or osteopenia.

Cited by 7 publications

References 10 publications

Bone metabolism in diabetes mellitus: focus on vitamin K2

Bone metabolism in diabetes mellitus: focus on vitamin K2

Effects of vitamin K₂ combined with methotrexate against mitogen‐activated peripheral blood mononuclear cells of healthy subjects and rheumatoid arthritis patients

Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis

Contact Info

Product

Resources

About

Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients

Abstract: Combined therapy with alendronate and VitK2 decreases bone metabolism marker levels and serum ucOC levels, and increases lumbar spine and femoral neck bone density in postmenopausal RA patients with abnormal ucOC levels and osteoporosis or osteopenia.

Cited by 7 publications

References 10 publications

Bone metabolism in diabetes mellitus: focus on vitamin K2

Bone metabolism in diabetes mellitus: focus on vitamin K2

Effects of vitamin K2 combined with methotrexate against mitogen‐activated peripheral blood mononuclear cells of healthy subjects and rheumatoid arthritis patients

Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis

Contact Info

Product

Resources

About

Effects of vitamin K₂ combined with methotrexate against mitogen‐activated peripheral blood mononuclear cells of healthy subjects and rheumatoid arthritis patients